Chemotherapy in low-grade gliomas

Aurélien Viaccoz, Alain Zingraff Lekoubou Looti, François Ducray

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Purpose of Review: This review summarizes the recent studies in adults' diffuse low-grade gliomas (LGGs) chemotherapy, including response assessment and potential predictive biomarkers of chemosensitivity. Recent Findings: Recent studies have confirmed that chemotherapy is an interesting treatment option in LGGs. About 25-50% of LGGs achieve radiological responses with temozolomide or a procarbazine-CCNU-vincristine (PCV) regimen. Clinical and quality-of-life improvements are commonly observed with more than half of the patients with epilepsy, demonstrating a significant reduction of seizure frequency. Dynamic volumetric studies have provided a better description of LGGs evolution after chemotherapy. They have shown that an ongoing volume decrease can be observed many months after chemotherapy discontinuation, particularly after PCV, raising the question of how and for how long should LGGs be treated. New response criteria have been defined by the Response Assessment in Neuro-Oncology group. In addition to 1p/19q codeletion and MGMT promoter methylation, IDH1 mutation might also be a potential predictive biomarker of chemosensitivity. Summary: It has now been widely accepted that chemotherapy is an interesting treatment option in LGGs. However, several questions remain unanswered regarding its optimal use. Ongoing phase III studies will allow a better delineation of the role of chemotherapy in LGGs and will also help to better determine the potential predictive value of a 1p/19q codeletion, a MGMT promoter methylation and an IDH1 mutation.

Original languageEnglish (US)
Pages (from-to)694-701
Number of pages8
JournalCurrent opinion in oncology
Volume24
Issue number6
DOIs
StatePublished - Nov 1 2012

Fingerprint

Glioma
Drug Therapy
Lomustine
Procarbazine
temozolomide
Vincristine
Methylation
Biomarkers
Mutation
Quality Improvement
Epilepsy
Seizures
Quality of Life
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Viaccoz, Aurélien ; Lekoubou Looti, Alain Zingraff ; Ducray, François. / Chemotherapy in low-grade gliomas. In: Current opinion in oncology. 2012 ; Vol. 24, No. 6. pp. 694-701.
@article{07204bddaa7449889e47906c5a7831ec,
title = "Chemotherapy in low-grade gliomas",
abstract = "Purpose of Review: This review summarizes the recent studies in adults' diffuse low-grade gliomas (LGGs) chemotherapy, including response assessment and potential predictive biomarkers of chemosensitivity. Recent Findings: Recent studies have confirmed that chemotherapy is an interesting treatment option in LGGs. About 25-50{\%} of LGGs achieve radiological responses with temozolomide or a procarbazine-CCNU-vincristine (PCV) regimen. Clinical and quality-of-life improvements are commonly observed with more than half of the patients with epilepsy, demonstrating a significant reduction of seizure frequency. Dynamic volumetric studies have provided a better description of LGGs evolution after chemotherapy. They have shown that an ongoing volume decrease can be observed many months after chemotherapy discontinuation, particularly after PCV, raising the question of how and for how long should LGGs be treated. New response criteria have been defined by the Response Assessment in Neuro-Oncology group. In addition to 1p/19q codeletion and MGMT promoter methylation, IDH1 mutation might also be a potential predictive biomarker of chemosensitivity. Summary: It has now been widely accepted that chemotherapy is an interesting treatment option in LGGs. However, several questions remain unanswered regarding its optimal use. Ongoing phase III studies will allow a better delineation of the role of chemotherapy in LGGs and will also help to better determine the potential predictive value of a 1p/19q codeletion, a MGMT promoter methylation and an IDH1 mutation.",
author = "Aur{\'e}lien Viaccoz and {Lekoubou Looti}, {Alain Zingraff} and Fran{\cc}ois Ducray",
year = "2012",
month = "11",
day = "1",
doi = "10.1097/CCO.0b013e328357f503",
language = "English (US)",
volume = "24",
pages = "694--701",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Chemotherapy in low-grade gliomas. / Viaccoz, Aurélien; Lekoubou Looti, Alain Zingraff; Ducray, François.

In: Current opinion in oncology, Vol. 24, No. 6, 01.11.2012, p. 694-701.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Chemotherapy in low-grade gliomas

AU - Viaccoz, Aurélien

AU - Lekoubou Looti, Alain Zingraff

AU - Ducray, François

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Purpose of Review: This review summarizes the recent studies in adults' diffuse low-grade gliomas (LGGs) chemotherapy, including response assessment and potential predictive biomarkers of chemosensitivity. Recent Findings: Recent studies have confirmed that chemotherapy is an interesting treatment option in LGGs. About 25-50% of LGGs achieve radiological responses with temozolomide or a procarbazine-CCNU-vincristine (PCV) regimen. Clinical and quality-of-life improvements are commonly observed with more than half of the patients with epilepsy, demonstrating a significant reduction of seizure frequency. Dynamic volumetric studies have provided a better description of LGGs evolution after chemotherapy. They have shown that an ongoing volume decrease can be observed many months after chemotherapy discontinuation, particularly after PCV, raising the question of how and for how long should LGGs be treated. New response criteria have been defined by the Response Assessment in Neuro-Oncology group. In addition to 1p/19q codeletion and MGMT promoter methylation, IDH1 mutation might also be a potential predictive biomarker of chemosensitivity. Summary: It has now been widely accepted that chemotherapy is an interesting treatment option in LGGs. However, several questions remain unanswered regarding its optimal use. Ongoing phase III studies will allow a better delineation of the role of chemotherapy in LGGs and will also help to better determine the potential predictive value of a 1p/19q codeletion, a MGMT promoter methylation and an IDH1 mutation.

AB - Purpose of Review: This review summarizes the recent studies in adults' diffuse low-grade gliomas (LGGs) chemotherapy, including response assessment and potential predictive biomarkers of chemosensitivity. Recent Findings: Recent studies have confirmed that chemotherapy is an interesting treatment option in LGGs. About 25-50% of LGGs achieve radiological responses with temozolomide or a procarbazine-CCNU-vincristine (PCV) regimen. Clinical and quality-of-life improvements are commonly observed with more than half of the patients with epilepsy, demonstrating a significant reduction of seizure frequency. Dynamic volumetric studies have provided a better description of LGGs evolution after chemotherapy. They have shown that an ongoing volume decrease can be observed many months after chemotherapy discontinuation, particularly after PCV, raising the question of how and for how long should LGGs be treated. New response criteria have been defined by the Response Assessment in Neuro-Oncology group. In addition to 1p/19q codeletion and MGMT promoter methylation, IDH1 mutation might also be a potential predictive biomarker of chemosensitivity. Summary: It has now been widely accepted that chemotherapy is an interesting treatment option in LGGs. However, several questions remain unanswered regarding its optimal use. Ongoing phase III studies will allow a better delineation of the role of chemotherapy in LGGs and will also help to better determine the potential predictive value of a 1p/19q codeletion, a MGMT promoter methylation and an IDH1 mutation.

UR - http://www.scopus.com/inward/record.url?scp=84868206990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868206990&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e328357f503

DO - 10.1097/CCO.0b013e328357f503

M3 - Review article

C2 - 22913972

AN - SCOPUS:84868206990

VL - 24

SP - 694

EP - 701

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 6

ER -